Patents by Inventor Patrick Reid
Patrick Reid has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11970694Abstract: Provided are linkers suitable for preparing a conjugate of a nucleic acid and a peptide as a translation product thereof in a reconstituted cell-free translation system in genotype-phenotype mapping (display methods), said linkers comprising a single-stranded structure region having a side chain base pairing with the base at the 3?-end of an mRNA at one end and a peptidyl acceptor region containing an amino acid attached to an oligo RNA consisting of a nucleotide sequence of ACCA via an ester bond at the other end, characterized in that the ester bond is formed by using an artificial RNA catalyst. Also provided are display methods using [mRNA]-[linker]-[peptide] conjugates assembled via such linkers.Type: GrantFiled: March 3, 2020Date of Patent: April 30, 2024Assignee: PeptiDream Inc.Inventors: Kenji Kashiwagi, Patrick Reid
-
Patent number: 11915821Abstract: This disclosure relates to a medical image viewer for incorporating multi-user collaboration features, such as in-image commenting and workspace sharing. An example method includes receiving a comment location including image coordinates and comment information associated with the comment from a user device. The comment information includes a text body, identify identity information related to the user, and a comment creation date. The example method further includes determining world coordinates based on the image coordinates, and storing the world coordinates and the comment information as a subset of header attributes of the DICOM image file.Type: GrantFiled: November 19, 2019Date of Patent: February 27, 2024Assignee: ARTERYS INC.Inventors: Fabien Rafael David Beckers, John Axerio-Cilies, Maud Josee Caroline Benaddi, Patrick Ross Corless, Shek Bun Law, Justin Reid, Derek John Scherger, Kendall Wu
-
Publication number: 20230416250Abstract: The present invention provides methods of preparing heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators, and compositions having low impurity levels.Type: ApplicationFiled: June 27, 2023Publication date: December 28, 2023Inventors: Hazel Joan Hunt, Gary Patrick Reid, Jeffrey Mark Dener, Adam Daisuke Gammack Yamagata, Gareth C. Sheppard
-
Publication number: 20220339279Abstract: Disclosed are recombinant proteins, compositions, vectors, kits, data analyses, and methods for inducing an immune response against, or detecting exposure to, SARS-CoV-2. In particular, the compositions, vectors, kits, data analyses and methods may be utilized to immunize subjects against disease associated with SARS-CoV-2 infection or to protect subjects from SARS-CoV-2 infection. In some embodiments, the recombinant proteins are useful in the production of antibodies against SARS-CoV-2, and for the detection of exposure to SARS-CoV-2.Type: ApplicationFiled: April 15, 2022Publication date: October 27, 2022Inventors: Kenneth Bayles, Gloria Borgstahl, Siddappa Byrareddy, Chittibabu Guda, St. Patrick Reid, Mara Jana Broadhurst, Andrew Schnaubelt
-
Publication number: 20210397313Abstract: A device implementing a system to render widget user interfaces for display of dynamic application content on a home screen includes a processor configured to identify a container associated with a first home screen, the container corresponding to an application. The processor is further configured to retrieve data describing a plurality of user interfaces, associated with respective times, of the application. The processor is further configured to render, based on the data, the plurality of the user interfaces in advance of the respective times. The processor is further configured to determine that the first home screen is currently displayed. The processor is further configured to select a first rendered user interface from the rendered user interfaces, wherein the respective time associated with the first rendered user interface corresponds to a current time. The processor is further configured to display the selected first rendered user interface on the first home screen.Type: ApplicationFiled: June 17, 2021Publication date: December 23, 2021Inventors: Neil N. DESAI, Nahir A. KHAN, Andrew Brett CATO, John LOUCH, Patrick Reid METCALFE, Antony J. DZERYN, David A. SCHAEFGEN, Jacob FRAIMOW, Nils Moshe Abraham HAYAT, Jacob Alan XIAO
-
Patent number: 11149066Abstract: Provided is a compound that can promote angiogenesis by inhibiting the function of TSP1, and is useful for the treatment or prophylaxis of diseases such as critical limb ischemia.Type: GrantFiled: September 13, 2017Date of Patent: October 19, 2021Assignees: DAIICHI SANKYO COMPANY, LIMITED, PEPTIDREAM INC.Inventors: Takahiro Yamaguchi, Yutaka Mori, Hironao Saito, Hideki Kubota, Akihiro Furukawa, Eri Otsuka, Yutaka Ishigai, Hiroshi Ijiri, Patrick Reid
-
Patent number: 10745692Abstract: An object of the present invention is to provide a method of producing a peptide containing a charged non-proteinogenic amino acid in a cell-free translation system, and the like. The present invention provides a method of producing a peptide containing a charged non-proteinogenic amino acid. It includes a step of expressing a peptide in a cell-free translation system including (i) at least one tRNA to which a non-proteinogenic amino acid having a protecting-group-introduced charged group has been bound and (ii) a nucleic acid that encodes the peptide and contains at least one codon corresponding to an anticodon of the tRNA; and a step of removing the protecting group of the non-proteinogenic amino acid residue contained in the peptide.Type: GrantFiled: August 4, 2014Date of Patent: August 18, 2020Assignees: The University of Tokyo, PeptiDream Inc.Inventors: Hiroshi Murakami, Takashi Kawakami, Patrick Reid, Toru Sasaki
-
Patent number: 10711268Abstract: An object of the present invention is to provide a method for producing a peptide library capable of incorporating an arbitrary number of arbitrary proteinogenic and/or non-proteinogenic amino acids in an arbitrary site. The invention provides a method for producing a peptide library including 1×106 or more kinds of peptides containing amino acids encoded by N1N2N3, including a step of preparing an mRNA library including mRNAs which encode peptides of the peptide library and each contain at least one N1N2N3; and a step of translating each mRNA of the mRNA library in a cell-free translation system added with tRNA containing an anticodon to any one of N1N2N3 codons and charged with an amino acid corresponding to the codon (wherein, N1, N2, and N3 are each independently selected from adenine (A), guanine (G), cytosine (C), and uracil (U) and an arbitrary amino acid is reassigned to each N1N2N3).Type: GrantFiled: May 12, 2014Date of Patent: July 14, 2020Assignees: The University of Tokyo, PeptiDream Inc.Inventors: Hiroshi Murakami, Takashi Kawakami, Patrick Reid, Toru Sasaki
-
Publication number: 20200199579Abstract: Provided are linkers suitable for preparing a conjugate of a nucleic acid and a peptide as a translation product thereof in a reconstituted cell-free translation system in genotype-phenotype mapping (display methods), said linkers comprising a single-stranded structure region having a side chain base pairing with the base at the 3?-end of an mRNA at one end and a peptidyl acceptor region containing an amino acid attached to an oligo RNA consisting of a nucleotide sequence of ACCA via an ester bond at the other end, characterized in that the ester bond is formed by using an artificial RNA catalyst. Also provided are display methods using [mRNA]-[linker]-[peptide] conjugates assembled via such linkers.Type: ApplicationFiled: March 3, 2020Publication date: June 25, 2020Inventors: Kenji Kashiwagi, Patrick Reid
-
Publication number: 20200131230Abstract: Provided is a compound that can promote angiogenesis by inhibiting the function of TSP1, and is useful for the treatment or prophylaxis of diseases such as critical limb ischemia.Type: ApplicationFiled: September 13, 2017Publication date: April 30, 2020Applicants: Daiichi Sankyo Company, Limited, PeptiDream Inc.Inventors: Takahiro YAMAGUCHI, Yutaka MORI, Hironao SAITO, Hideki KUBOTA, Akihiro FURUKAWA, Eri OTSUKA, Yutaka ISHIGAI, Hiroshi IJIRI, Patrick REID
-
Patent number: 10632187Abstract: Disclosed is a hemagglutinin-binding peptide producing an anti-influenza virus effect higher than that of existing peptides. Also disclosed are hemagglutinin-binding peptides comprising a polypeptide having any of the following amino acid sequences (i) to (iv): (i) Thr-MeGly-Asp-MePhe-MePhe-Ser-MeSer-His-Tyr-Thr-Val-Pro-Arg (SEQ ID NO: 1); (ii) Arg-Val-Ser-MePhe-Thr-Tyr-MePhe-MeSer-Tyr-Thr-Pro-Ser (SEQ ID NO: 2); (iii) an amino acid sequence with deletions, additions, or substitutions of one or several amino acids in SEQ ID NO: 1 or 2; and (iv) an amino acid sequence having 90% or more sequence identity to that of SEQ ID NO: 1 or 2.Type: GrantFiled: May 3, 2019Date of Patent: April 28, 2020Assignees: PeptiDream Inc., Tokyo Metropolitan Institute of Medical ScienceInventors: Kiichi Kubota, Patrick Reid, Michinori Kohara, Keiichi Masuya, Masaki Ohuchi
-
Patent number: 10493071Abstract: There is provided the use of compounds of formula I wherein R1, R2, R3 and X have meanings given in the description, for the preparation of a medicament for killing clinically latent microorganisms. There is also provided the use of compounds of formula I for treating microbial infections, as well as certain compounds of formula I per se.Type: GrantFiled: May 30, 2017Date of Patent: December 3, 2019Assignee: HELPERBY THERAPEUTICS LIMITEDInventors: Petra Helga Beck, Marc Barry Brown, David Edward Clark, Anthony Coates, Hazel Joan Dyke, Yanmin Hu, Derek John Londesbrough, Keith Mills, Thomas David Pallin, Gary Patrick Reid, Gerlinda Stoddart
-
Publication number: 20190282688Abstract: Disclosed is a hemagglutinin-binding peptide producing an anti-influenza virus effect higher than that of existing peptides. Also disclosed are hemagglutinin-binding peptides comprising a polypeptide having any of the following amino acid sequences (i) to (iv): (i) Thr-MeGly-Asp-MePhe-MePhe-Ser-MeSer-His-Tyr-Thr-Val-Pro-Arg (SEQ ID NO: 1); (ii) Arg-Val-Ser-MePhe-Thr-Tyr-MePhe-MeSer-Tyr-Thr-Pro-Ser (SEQ ID NO: 2); (iii) an amino acid sequence with deletions, additions, or substitutions of one or several amino acids in SEQ ID NO: 1 or 2; and (iv) an amino acid sequence having 90% or more sequence identity to that of SEQ ID NO: 1 or 2.Type: ApplicationFiled: May 3, 2019Publication date: September 19, 2019Inventors: Kiichi Kubota, Patrick Reid, Michinori Kohara, Keiichi Masuya, Masaki Ohuchi
-
Patent number: 10328143Abstract: Object of the present invention is to provide a hemagglutinin-binding peptide producing an anti-influenza virus effect higher than that of existing peptides. The present invention provides, for example, a hemagglutinin-binding peptide comprising a polypeptide having any of the following amino acid sequences (i) to (iv): (i) Thr-MeGly-Asp-MePhe-MePhe-Ser-MeSer-His-Tyr-Thr-Val-Pro-Arg (SEQ ID NO: 1); (ii) Arg-Val-Ser-MePhe-Thr-Tyr-MePhe-MeSer-Tyr-Thr-Pro-Ser (SEQ ID NO: 2); (iii) an amino acid sequence with deletions, additions, or substitutions of one or several amino acids in SEQ ID NO: 1 or 2; and (iv) an amino acid sequence having 90% or more sequence identity to that of SEQ ID NO: 1 or 2.Type: GrantFiled: October 23, 2015Date of Patent: June 25, 2019Assignees: PeptiDream Inc., Tokyo Metropolitan Institute of Medical ScienceInventors: Kiichi Kubota, Patrick Reid, Michinori Kohara, Keiichi Masuya, Masaki Ohuchi
-
Publication number: 20170333549Abstract: Object of the present invention is to provide a hemagglutinin-binding peptide producing an anti-influenza virus effect higher than that of existing peptides. The present invention provides, for example, a hemagglutinin-binding peptide comprising a polypeptide having any of the following amino acid sequences (i) to (iv): (i) Thr-MeGly-Asp-MePhe-MePhe-Ser-MeSer-His-Tyr-Thr-Val-Pro-Arg (SEQ ID NO: 1); (ii) Arg-Val-Ser-MePhe-Thr-Tyr-MePhe-MeSer-Tyr-Thr-Pro-Ser (SEQ ID NO: 2); (iii) an amino acid sequence with deletions, additions, or substitutions of one or several amino acids in SEQ ID NO: 1 or 2; and (iv) an amino acid sequence having 90% or more sequence identity to that of SEQ ID NO: 1 or 2.Type: ApplicationFiled: October 23, 2015Publication date: November 23, 2017Inventors: Kiichi Kubota, Patrick Reid, Michinori Kohara, Keiichi Masuya, Masaki Ohuchi
-
Patent number: 9815867Abstract: An object of the present invention is to provide a VEGFR2 inhibitor peptide having high specificity and available at a low cost.Type: GrantFiled: September 2, 2013Date of Patent: November 14, 2017Assignees: The University of Tokyo, Peptidream Inc.Inventors: Hiroshi Murakami, Takashi Kawakami, Takahiro Ishizawa, Hiroaki Suga, Patrick Reid
-
Publication number: 20170258784Abstract: There is provided the use of compounds of formula I wherein R1, R2, R3 and X have meanings given in the description, for the preparation of a medicament for killing clinically latent microorganisms. There is also provided the use of compounds of formula I for treating microbial infections, as well as certain compounds of formula I per se.Type: ApplicationFiled: May 30, 2017Publication date: September 14, 2017Applicant: HELPERBY THERAPEUTICS LIMITEDInventors: Petra Helga BECK, Marc Barry BROWN, David Edward CLARK, Anthony COATES, Hazel Joan DYKE, Yanmin HU, Derek John LONDESBROUGH, Keith MILLS, Thomas David PALLIN, Gary Patrick REID, Gerlinda STODDART
-
Patent number: 9694006Abstract: There is provided the use of compounds of formula I wherein R1, R2, R3 and X have meanings given in the description, for the preparation of a medicament for killing clinically latent microorganisms. There is also provided the use of compounds of formula I for treating microbial infections, as well as certain compounds of formula I per se.Type: GrantFiled: May 17, 2012Date of Patent: July 4, 2017Assignee: HELPERBY THERAPEUTICS LIMITEDInventors: Petra Helga Beck, Marc Barry Brown, David Edward Clark, Anthony Coates, Hazel Joan Dyke, Yanmin Hu, Derek John Londesbrough, Keith Mills, Thomas David Pallin, Gary Patrick Reid, Gerlinda Stoddart
-
Patent number: 9657008Abstract: The invention concerns compounds of Formula (I) or pharmaceutically-acceptable salts thereof, wherein R1 and R2 have any of the meanings defined hereinbefore in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the treatment of cell proliferative disorders.Type: GrantFiled: August 31, 2015Date of Patent: May 23, 2017Assignee: AstraZeneca ABInventors: Bernard Christophe Barlaam, Benedicte Delouvrie, Craig Steven Harris, Christine Marie Paul Lambert-Van der Brempt, Gilles Ouvry, Gary Patrick Reid, David Berry, Gary Peter Tomkinson
-
Publication number: 20160289668Abstract: An object of the present invention is to provide a method of producing a peptide containing a charged non-proteinogenic amino acid in a cell-free translation system, and the like. The present invention provides a method of producing a peptide containing a charged non-proteinogenic amino acid. It includes a step of expressing a peptide in a cell-free translation system including (i) at least one tRNA to which a non-proteinogenic amino acid having a protecting-group-introduced charged group has been bound and (ii) a nucleic acid that encodes the peptide and contains at least one codon corresponding to an anticodon of the tRNA; and a step of removing the protecting group of the non-proteinogenic amino acid residue contained in the peptide.Type: ApplicationFiled: August 4, 2014Publication date: October 6, 2016Inventors: Hiroshi Murakami, Takashi Kawakami, Patrick Reid, Toru Sasaki